RALEIGH, N.C., May 21, 2020 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals announced today that the United States Patent and Trademark Office (USPTO) has issued two critical patents related to its lead asset, Kyzatrex®*. Kyzatrex® is an oral Testosterone Replacement Therapy (TRT) that uses an innovative formulation to improve effectiveness and safety.
These allowed claims will provide strong IP protection to December 2030, over 8 years of potential commercial runway. They supplement Marius Pharmaceuticals’ already robust global patent portfolio for Kyzatrex®, which includes granted patents in the European Union, Canada, China, Taiwan, Japan, New Zealand, and other key markets, and pending applications in India, and the US. Marius Pharmaceuticals’ patent portfolio includes filings that extend protection to 2033, with the potential to extend protection out to 2040.
The allowed claims protect Kyzatrex ®, a progressive formula configured to boost bioavailability and provide a favorable pharmacokinetic (PK) profile compared to other therapeutic choices. Om Dhingra, Chief Executive Officer of Marius stated “This innovation is truly exceptional as we have created a formulation with a unique PK profile which we believe drives important clinical significance.”
Marius Pharmaceuticals’ Chief Financial Officer Shalin Shah said “We are very pleased to strengthen the intellectual property portfolio for Kyzatrex® and excited that it has tremendous potential to be a differentiated and unique option in the TRT space. We are also drawing a line in the sand between a new treatment paradigm and old testosterone therapies.”
Marius Pharmaceuticals has recently completed its pivotal Phase 3 study for Kyzatrex® and intends to submit its New Drug Application (NDA) to the Food & Drug Administration (FDA).
Kyzatrex® is an experimental therapy for the treatment of primary and secondary hypogonadism (congenital or acquired). Testosterone is a crucial hormone that plays a crucial role in human growth and development and a wide range of other functions including metabolic and cardiovascular. Sources estimate that 15 million men in the United States suffer from hypogonadism, but only approximately 10% are currently treated. The co-morbidities of men suffering from hypogonadism are also a significant burden on patients and the healthcare system, these include Type 2 Diabetes and other serious chronic conditions.
Currently, marketed treatments are dominated by painful injections and messy topical applications with transference risk. Kyzatrex® is an orally administered therapy, which avoids those drawbacks. Market research points to 93% of patients indicating they would ask their physician about Kyzatrex® and more than half would consider a switch from their current regimen.
About Marius Pharmaceuticals
Marius pharmaceuticals is a cutting-edge biopharma company focusing on treating widespread conditions that have been triggered primarily through Androgen deficiency. Our pipeline consists of assets focused on inflammation while our commercial arm is at the forefront of data science technologies core to the commercialization of our lead asset Kyzatrex®.
*Kyzatrex is a tentative Tradename currently under review with the FDA
Contact Us Today For A Free Consultation
Once you have completing the above contact form, for security purposes and confirmation, please confirm your information by calling us.
Please call now: 1-800-380-5339.
Welcoming You To Our Clinic, Professor Tom Henderson.
- Slow Aging with Growth Hormone - July 17th, 2022
- Cheaping Out on HGH Therapy – JUST DON’T DO IT - July 12th, 2022
- Hormone Impacts And Function Of HGH - July 10th, 2022
- General Physician Versus Hormone Specialist – Some Symptoms Require a Specialist to Heal - March 18th, 2022
- An Introduction to Growth Hormone - October 27th, 2021
- Growth Hormone and Pneumonia - October 27th, 2021
- Growth Hormone and Testosterone Replacement Therapy - October 27th, 2021
- Growth Hormone and the Hypothalamus Gland - October 27th, 2021
- Growth Hormone and the Law - October 27th, 2021
- Growth Hormone and Gene Therapy - October 26th, 2021
- What Men Need To Know About Testosterone And Growth Hormone - October 26th, 2021
- Growth Hormone Explained - October 26th, 2021
- The Best Ways to Boost Growth Hormone - October 26th, 2021
- Growth Hormone Sprays - October 26th, 2021
- Growth Hormone Dosage - October 26th, 2021
- Insulin-Similar Growth Factor Benefits - October 26th, 2021
- The Benefits of IGF-1 - October 26th, 2021
- Hormone Replacement Therapy is Safe - October 26th, 2021
- Estrogen HRT May Reduce Breast Cancer Risk - October 26th, 2021
- Growth Hormone Therapy Reverses Biological Age In Groundbreaking Study - October 25th, 2021
- Human Growth Hormone Secretagogue: Sermorelin - October 25th, 2021
- Early Hormone Replacement Therapy May Lower Alzheimer Risk - October 25th, 2021
- Comprehensive Hormone Replacement Therapy with Tesamorelin - September 18th, 2021
- Risks of Hormones in Early Menopause Challenged - August 24th, 2021
- Heart Benefits From Hormone Replacement Therapy? - August 18th, 2021
- New Research: Cognitive Therapy Could Reduce Menopausal Hot Flashes - August 16th, 2021
- A Toxic Hormone is Altering the Sex and Reproduction of Aquatic Life in United States Streams - August 16th, 2021
- Act Now to Prevent the Increasingly Common Condition of Hypothyroidism - June 21st, 2021
- The HGH Recommended Medical Dosage - The Importance of Blood Work - May 25th, 2021
- Hormone Replacement Therapy Safe, Study Suggests - May 24th, 2021
- HGH Secretagogue - May 22nd, 2021
- Androgel : Men Getting Their Mojo Back! - May 21st, 2021
- Hormone Therapy May Help Cut Alzheimer's Risk - May 18th, 2021
- Finally Explained: The Mysterious Pineal Gland - April 30th, 2021
- Andropause From The Wikipedia Encyclopedia - April 12th, 2021
- The Importance of Luteinizing Hormone - April 11th, 2021
- Melatonin: The Body's Master Clock - April 8th, 2021
- LCN2 Hormone Suppresses Hunger and Discourages Overeating - April 7th, 2021
- New Research on Hormone Replacement Therapy - March 12th, 2021
Word Count: 470